Last reviewed · How we verify
Pioglitazone plus exenatide
At a glance
| Generic name | Pioglitazone plus exenatide |
|---|---|
| Also known as | actos and bydureon |
| Sponsor | Dr. Muhammad Abdulghani |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Nausea
- Diarrhoea
- Influenza
- Upper Respiratory Tract Infection
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE4)
- Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function (PHASE4)
- Incretin-based Drugs and Acute Pancreatitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone plus exenatide CI brief — competitive landscape report
- Pioglitazone plus exenatide updates RSS · CI watch RSS
- Dr. Muhammad Abdulghani portfolio CI